Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types
or
Treatments

Treatment Name: Rucaparib (Rubraca®)

Rucaparib (Rubraca®) is a Chemotherapy Regimen for Ovarian Cancer

Thank you for visiting our Rucaparib (Rubraca®) page.

  • If you are interested in seeing the full treatment regimen page for Rucaparib (Rubraca®) sooner rather than later, please click here to cast your vote for this specific regimen.
  • Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for Rucaparib (Rubraca®) shown below will prove useful in the meantime.

Thank you for your continued support!

Sincerely,
The ChemoExperts Team

References

1) Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology. 2017;147:267-275.

2) Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949-61.

Created: February 16, 2019 Updated: February 16, 2019

What is Ovarian Cancer?

What is Ovarian Cancer?
A disease of the cells found in the ovaries in women. Ovarian cancer is not common, but is the fifth leading cause of cancer related death in women. The exact cause is not known, however risk factors include: older age, obesity, first period at an early age, late menopause, hormone replacement therapy (HRT) after menopause, family history, and genetic causes such as the BRCA (pronounced "bracka") mutation. The use of oral contraceptives or having one or more full-term pregnancies can decrease the risk of ovarian cancer.

The stage of ovarian cancer can vary at diagnosis and throughout treatment. Ovarian cancer is staged using the Tumor, Node, Metastasis (TNM) staging system, as well as Stage Grouping I, II, III, or IV. Staging systems describe the extent of cancer throughout the body and help doctors determine which treatments to offer. The effectiveness of the treatment may depend upon the stage at diagnosis.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

Common starting doses for Rucaparib (Rubraca®)

  • Usual rucaparib (Rubraca®) starting dose: 600 mg (two 300-mg tablets) by mouth twice daily